104  0 Kommentare ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022

ERYTECH’s shareholders are hereby informed of the Annual General Meeting which will be held on June 24, 2022 at 09:00am CEST at the Hôtel Intercontinental Paris – Le Grand, 2 rue Scribe, 75009 Paris (FRANCE).

Shareholders may participate in the General Meeting as follows:

1. Attend in person;
   
   
2. Voting by mail or by internet on the secure voting platform Votaccess; or
   
   
3. Give a proxy to any individual or legal entity of their choice, under the applicable legal and regulatory conditions, or give a proxy to the Chairman of the Shareholders' Meeting. The Chairman will then vote on their behalf in favor of the adoption of the draft resolutions presented or approved by the Board of Directors and against the adoption of all other draft resolutions.
   
   

Availability of the documents for the Shareholders’ Meeting

The notice of meeting including the agenda and the draft resolutions, together with the principal details for attending and voting at the Combined Shareholders’ Meeting was published in the French Bulletin of Legal Announcements no. 59 on May 18, 2022.

Shareholders have access to the preparatory and information documents for the Shareholders’ Meeting as provided for by law and the regulations. They may also be viewed on the Company’s website at: https://investors.erytech.com/general-meeting.

Lesen Sie auch

Buy the Dip!

Nvidia setzt zum nächsten Kursfeuerwerk an: Morgan Stanley kauft zu

heute 17:50

Übernahme-Krimi

Anglo-BHP-Deal: Jetzt mischt auch ein Hedgefonds mit

heute 16:45

Albemarle vor den Zahlen

Nimmt die Trendwende am Lithium-Markt endlich Form an?

heute 16:00

Earnings

AbbVie: Gewinn pro Aktie steigt um 492,3 Prozent – Prognose angehoben!

heute 15:15

Shareholders are kindly advised to consult this section on a regular basis, as it may be updated to specify the final terms and conditions of participation in this Shareholders' Meeting, in accordance with sanitary and/or legal and regulatory requirements.

About ERYTECH and eryaspase (GRASPA) www.erytech.com

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.